Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03439657 · ClinicalTrials.gov registry record · Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

A Phase 3 study of Herpes Zoster, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
913
Enrollment target
13
Study locations

NCT03439657 is a Phase 3 study of Herpes Zoster that has completed, run by GlaxoSmithKline. The registered enrollment target is 913 participants, below the 2,116-participant average among 16 other Herpes Zoster trials with a reported enrollment target (57% lower). The trial reports 13 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03439657, a Phase 3 study of Herpes Zoster, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
913 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as compared to the control group where the two HZ/su doses are administered subsequent to Prevenar13.

Conditions Studied

Herpes Zoster

Interventions

  • BIOLOGICAL HZ/su vaccine GSK1437173A
  • BIOLOGICAL Prevenar13

Study Locations (13)

Other

  • GSK Investigational Site - Rakvere
  • GSK Investigational Site - Tallinn
  • GSK Investigational Site - Tartu

North Rhine-Westphalia

  • GSK Investigational Site - Essen
  • GSK Investigational Site - Goch

Massachusetts

  • GSK Investigational Site - Marlborough

North Carolina

  • GSK Investigational Site - Salisbury

South Carolina

  • GSK Investigational Site - Spartanburg

Nova Scotia

  • GSK Investigational Site - Truro

Quebec

  • GSK Investigational Site - Sherbrooke

Baden-Wurttemberg

  • GSK Investigational Site - Weinheim

Trial Details

FieldValue
Enrollment Target 913 participants
Start Date 2018-04-12
Est. Completion 2020-03-03
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03439657

The ClinicalTrials.gov registry entry for NCT03439657 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 913 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,116-participant average among 16 other Herpes Zoster trials with a reported enrollment target (57% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which HZ/su vaccine GSK1437173A is the first listed.

NCT03439657 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Other, North Rhine-Westphalia, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03439657 about?

NCT03439657 is a clinical study titled "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older". The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as compared to the control group where the two HZ/su doses are administered...

What is the current status of trial NCT03439657?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 913 participants. The study started on 2018-04-12. Estimated completion is 2020-03-03.

What conditions does trial NCT03439657 study?

This clinical trial studies the following conditions: Herpes Zoster.

What interventions are being tested in trial NCT03439657?

The interventions under investigation include: HZ/su vaccine GSK1437173A (BIOLOGICAL), Prevenar13 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03439657?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03439657 being conducted?

This trial has 13 study locations across Massachusetts, North Carolina, South Carolina, Nova Scotia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Herpes Zoster

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Herpes Zoster

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.